Genetic Determinants of Response to Warfarin during Initial Anticoagulation | Zendy

Ute I. Schwarz | Zendy; Marylyn D. Ritchie | Zendy; Yuki Bradford | Zendy; Chun Li | Zendy; Scott Dudek | Zendy; Amy Frye-Anderson | Zendy; Richard B. Kim | Zendy; Dan M. Roden | Zendy; C. Michael Stein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

Author(s) -

Ute I. Schwarz,

Marylyn D. Ritchie,

Yuki Bradford,

Chun Li,

Scott Dudek,

Amy Frye-Anderson,

Richard B. Kim,

Dan M. Roden,

C. Michael Stein

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0708078

Subject(s) - vkorc1 , warfarin , cyp2c9 , vitamin k epoxide reductase , medicine , therapeutic index , haplotype , pharmacogenetics , genotype , pharmacology , biology , cytochrome p450 , atrial fibrillation , genetics , drug , metabolism , gene

Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research